News Releases

Ultralife Corporation
Nov 01, 2018
Ultralife Corporation Reports Third Quarter Results

Board of Directors Authorizes Share Repurchase Program

NEWARK, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:  ULBI) reported operating income of $1.5 million on revenue of $20.3 million for the third quarter ended September 30, 2018.  For the third quarter of 2017, the Company reported operating income of $1.3 million on revenue of $21.0 million

“In the third quarter, Ultralife grew net income 30% and EPS 26% driven by a 25% increase in Communications Systems revenues, while overall revenue slightly declined.  These double-digit earnings gains demonstrate the ability of our leveraged business model to deliver increases in profitability even though sales may fluctuate by business unit quarter to quarter,” said Michael D. Popielec, President and Chief Executive Officer. “We are also delighted about the two recently announced Communications Systems delivery contracts totaling $19.2 million to supply our Vehicle Amplifier-Adaptors and Mounted Power Amplifiers for the U.S. Army, as well as the $9.5 million IDIQ contract to supply our communication kits for an undisclosed branch of the U.S. Department of Defense.  We remain focused on our revenue diversification strategy, pursuing commercial opportunities and government/defense opportunities as U.S. spending continues to recover, and are positioned to deliver another year of profitable growth in 2018.”

Third Quarter 2018 Financial Results

Revenue was $20.3 million, a decrease of $0.7 million, or 3.4%, compared to $21.0 million for the third quarter of 2017 reflecting lower commercial sales.  Battery & Energy Products sales decreased $1.3 million, or 7.1%, to $17.3 million compared to $18.6 million last year due primarily to lower non-U.S. government/defense and 9-Volt battery sales, partially offset by increases in U.S. government/defense and core medical sales.  Communications Systems sales grew 25.1% to $3.0 million compared to $2.4 million for the same period last year reflecting an increase in shipments of core products such as our 20-watt amplifiers and universal vehicle adaptors. 

Gross profit was $6.0 million, or 29.7% of revenue, compared to $6.3 million, or 29.7% of revenue, for the same quarter a year ago.  Battery & Energy Products’ gross margin was 27.2%, compared to 27.9% last year, and Communications Systems gross margin was 44.0%, the same as last year.

Operating expenses were $4.5 million compared to $5.0 million last year, a decrease of 9.0%, reflecting continued tight control over discretionary spending in line with our business model.  Operating expenses were 22.3% of revenue compared to 23.7% of revenue for the year earlier period.

Operating income was $1.5 million compared to $1.3 million last year, an increase of 18.7%, and operating margin was 7.4% compared to 6.0% last year.

Net income was $1.4 million, or $0.09 per share, compared to net income of $1.1 million, or $0.07 per share, for the third quarter of 2017.    Earnings per share for the trailing twelve-month period increased to $.57 compared to $.55 at the end of the second quarter of 2018, with both periods reflecting the $.12 favorable impact of the Tax Cuts and Jobs Act in the fourth quarter of 2017.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, of $2.5 million, or 12.2% of sales, grew 25% over the $2.0 million, or 9.4% of sales, reported last year. 

See the “Non-GAAP Financial Measure – Adjusted EBITDA” section of this release for a reconciliation of Adjusted EBITDA to Net Income Attributable to Ultralife Corporation.

Share Repurchase Program

Ultralife’s Board of Directors has authorized the repurchase of up to 2.5 million shares of the Company’s common stock over a period not to exceed twelve months.  Share repurchases, if any, will be made in accordance with SEC Rule 10b-18 using a variety of methods, which may include open market purchases, privately negotiated transactions or block trades, or any combination of such methods, in accordance with applicable insider trading and other securities laws and regulations.

The timing and actual number of shares repurchased will depend on a variety of factors including price, market conditions and applicable legal requirements. The share repurchase program does not obligate the Company to repurchase any specific number of shares and may be suspended or terminated at any time without prior notice.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include:  potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances.  Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K. 

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
(Unaudited)
   
ASSETS 
       
  September 30,
2018
  December 31,
2017
Current Assets:      
Cash $25,454   $18,330
Trade Accounts Receivable, Net 14,533   14,657
Inventories 23,118   26,326
Prepaid Expenses and Other Current Assets 2,900   2,603
Total Current Assets 66,005   61,916
       
Property, Equipment and Improvements, Net 8,792   7,570
Goodwill, Intangibles and Other Assets 26,999   27,700
Total Assets $101,796   $97,186
       
 
LIABILITIES AND SHAREHOLDERS' EQUITY 
 
Current Liabilities:  
Accounts Payable $7,260   $8,787
Accrued Compensation and Related Benefits 1,641   2,413
Accrued Expenses and Other Current Liabilities 3,463   3,039
Total Current Liabilities 12,364   14,239
Deferred Income Taxes and Other Non-Current Liabilities 3,936   3,898
Total Liabilities 16,300   18,137
       
Shareholders' Equity:      
Common Stock 1,998   1,966
Capital in Excess of Par Value 182,246   180,211
Accumulated Deficit (77,709)   (82,894)
Accumulated Other Comprehensive Loss (2,473)   (1,611)
Treasury Stock (18,469)   (18,469)
Total Ultralife Equity 85,593   79,203
Non-Controlling Interest (97)   (154)
Total Shareholders’ Equity 85,496   79,049
       
Total Liabilities and Shareholders' Equity $101,796   $97,186
       


ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited) 
               
  Three-Month Periods Ended   Nine-Month Periods Ended
  September   October   September   October
  30,   1,   30,   1,
  2018   2017   2018   2017
Revenues:              
Battery & Energy Products $17,289   $18,616   $52,344   $52,977
Communications Systems 3,041   2,431   13,919   10,045
  Total Revenues 20,330   21,047   $66,263   $63,022
               
Cost of Products Sold:              
Battery & Energy Products 12,587   13,430   37,680   38,119
Communications Systems 1,702   1,362   8,710   5,537
  Total Cost of Products Sold 14,289   14,792   46,390   43,656
               
Gross Profit 6,041   6,255   19,873   19,366
               
Operating Expenses:              
Research and Development 1,099   1,355   3,417   3,678
Selling, General and Administrative 3,442   3,637   10,968   11,262
Total Operating Expenses 4,541   4,992   14,385   14,940
               
Operating Income 1,500   1,263   5,488   4,426
               
Other (Income) Expense (21)   58   27   200
Income Before Income Tax Provision 1,521   1,205   5,461   4,226
               
Income Tax Provision 86   104   219   370
               
Net Income 1,435   1,101   5,242   3,856
               
Net Income Attributable to Non-Controlling Interest 27   3   57   8
               
Net Income Attributable to Ultralife Corporation $1,408   $1,098   $5,185   $3,848
               
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic $.09   $.07   $.33   $.25
               
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted $.09   $.07   $.32   $.24
               
Weighted Average Shares Outstanding – Basic 15,952   15,564   15,859   15,495
               
Weighted Average Shares Outstanding – Diluted 16,523   15,971   16,407   15,818
               

Non-GAAP Financial Measure – Adjusted EBITDA

In evaluating our business, we consider and use Adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define Adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense. We reconcile Adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under U.S. generally accepted accounting principles (“U.S. GAAP”).  Neither current nor potential investors in our securities should rely on Adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjusted EBITDA to net income attributable to Ultralife.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(In Thousands)
(Unaudited)

  Three-Month Periods Ended   Nine-Month Periods Ended
  September 30,   October 1,   September 30,   October 1,
  2018   2017   2018   2017
               
Net Income Attributable to Ultralife Corporation $1,408   $1,098   $5,185   $3,848
Adjustments:              
Interest and Financing Expense, Net 13   38   67   147
Income Tax Provision 86   104   219   370
Depreciation Expense 496   497   1,476   1,507
Amortization of Intangible Assets and  Financing Fees 106   115   327   357
Stock-Based Compensation Expense 363   133   707   529
Adjusted EBITDA $2,472   $1,985   $7,981   $6,758
               


Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com
                                                                      Investor Relations Contact:
LHA
Jody Burfening
(212) 838-3777
jburfening@lhai.com
     

Ultralife Corporation logo

Source: Ultralife Corporation